Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.
作者： Ivan Gentile , Antonio Riccardo Buonomo , Federico Borgia , Giuseppe Castaldo , Guglielmo Borgia
DOI: 10.1517/13543784.2014.892581
关键词:
摘要: Introduction: About 150,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). HCV infection can lead to liver cirrhosis, hepatocellular carcinoma and death. Treatment was based previously only on pegylated interferon combined other antiviral drugs. Recently, the first interferon-free combination for patients genotype 2 or 3 approved in USA Europe, several molecules an advanced phase of clinical development. Areas covered: This review focuses pharmacokinetics, pharmacodynamics tolerability ledipasvir, inhibitor nonstructural 5A protein. The authors also highlight drug's safety resistance profile. Expert opinion: pharmacokinetic profile activity ledipasvir ideal. However, given high rate natural drug-related ledipasvir-resistant mutations, is administered regimens drugs, which resulted a cure up 100%. While ...
informahealthcare.com
core.ac.uk 参考文章(63)
Gentile I, Scarica S, Foggia M, Reynaud L, Borgia G, Di Flumeri G, Frangiosa A, Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. The Italian journal of urology and nephrology. ,vol. 65, pp. 83- 84 ,(2013)
Ivan Gentile, Alfonso De Stefano, Giusy Di Flumeri, Antonio Riccardo Buonomo, Chiara Carlomagno, Filomena Morisco, Sabino De Placido, Guglielmo Borgia, None, Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. in Vivo. ,vol. 27, pp. 527- 529 ,(2013)
X TONG, R CHASE, A SKELTON, T CHEN, J WRIGHTMINOGUE, B MALCOLM, Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research. ,vol. 70, pp. 28- 38 ,(2006) , 10.1016/J.ANTIVIRAL.2005.12.003
Christophe Hézode, Hélène Fontaine, Céline Dorival, Dominique Larrey, Fabien Zoulim, Valérie Canva, Victor de Ledinghen, Thierry Poynard, Didier Samuel, Marc Bourlière, Jean-Pierre Zarski, Jean-Jacques Raabe, Laurent Alric, Patrick Marcellin, Ghassan Riachi, Pierre-Henri Bernard, Véronique Loustaud-Ratti, Sophie Métivier, Albert Tran, Lawrence Serfaty, Armand Abergel, Xavier Causse, Vincent Di Martino, Dominique Guyader, Damien Lucidarme, Véronique Grando-Lemaire, Patrick Hillon, Cyrille Feray, Thong Dao, Patrice Cacoub, Isabelle Rosa, Pierre Attali, Ventzislava Petrov-Sanchez, Yoann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat, Jean-Pierre Bronowicki, CUPIC Study Group, None, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 Journal of Hepatology. ,vol. 59, pp. 434- 441 ,(2013) , 10.1016/J.JHEP.2013.04.035
N. Coppola, A. Marrone, M. Pisaturo, M. Starace, G. Signoriello, I. Gentile, L. E. Adinolfi, E. Sagnelli, R. Zampino, Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection European Journal of Clinical Microbiology & Infectious Diseases. ,vol. 33, pp. 559- 567 ,(2014) , 10.1007/S10096-013-1985-7
Robert Flisiak, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Emerging treatments for hepatitis C Expert Opinion on Emerging Drugs. ,vol. 18, pp. 461- 475 ,(2013) , 10.1517/14728214.2013.847089
G.T. Everson, A.M. Di Bisceglie, J.M. Vierling, F. Hsieh, J.D. Trenkle, B. Kanwar, M. Subramanian, J.G. McHutchison, R.H. Ghalib, V.K. Rustgi, P.Y. Kwo, 13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION Journal of Hepatology. ,vol. 58, pp. S6- ,(2013) , 10.1016/S0168-8278(13)60015-X
K.A. Wong, A. Worth, D.M. Brainard, E. Lawitz, M.D. Miller, H. Mo, 1215 PERSISTENCE OF NS5A GS-5885 DRUG RESISTANCE MUTATIONS FOLLOWING 3 DAYS OF MONOTHERAPY IN GENOTYPE-1 HCV PATIENTS IS DEPENDENT ON THE HCV SUBTYPE AND SPECIFIC MUTATION Journal of Hepatology. ,vol. 56, ,(2012) , 10.1016/S0168-8278(12)61227-6
Savino Bruno, Tommaso Stroffolini, Massimo Colombo, Simona Bollani, Luisa Benvegnù, Giuseppe Mazzella, Antonio Ascione, Teresa Santantonio, Felice Piccinino, Pietro Andreone, Alessandra Mangia, Giovanni B. Gaeta, Marcello Persico, Stefano Fagiuoli, Piero L. Almasio, , Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study Hepatology. ,vol. 45, pp. 579- 587 ,(2007) , 10.1002/HEP.21492
Benjamin Maasoumy, Heiner Wedemeyer, Natural history of acute and chronic hepatitis C. Best Practice & Research in Clinical Gastroenterology. ,vol. 26, pp. 401- 412 ,(2012) , 10.1016/J.BPG.2012.09.009